Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 8 March 2024, including: Bayer AG won’t split, for now; Pfizer Inc.’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and Bristol Myers Squibb Company’s CEO gives his views on India.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Bayer Boss Rules Out Divisions Split For Now" - Scrip, 5 Mar, 2024.)
(Also see "A Sneak Peak At Pfizer’s Next-Generation ADC Pipeline" - Scrip, 1 Mar, 2024.)
(Also see "In Investing, Oncology Is Still King, But Other Indications Joining The Royal Court" - Scrip, 1 Mar, 2024.)
(Also see "Say Goodbye To NASH And Hello To MASH" - Scrip, 6 Mar, 2024.)
(Also see "BMS’ Boerner Bets On AI-Driven R&D In India, Points To Potential For MS, Lupus Drugs" - Scrip, 4 Mar, 2024.)